These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 39129938)
1. Machine Learning-Based Personalized Prediction of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation. Sato M; Tateishi R; Moriyama M; Fukumoto T; Yamada T; Nakagomi R; Kinoshita MN; Nakatsuka T; Minami T; Uchino K; Enooku K; Nakagawa H; Shiina S; Ninomiya K; Kodera S; Yatomi Y; Koike K Gastro Hep Adv; 2022; 1(1):29-37. PubMed ID: 39129938 [TBL] [Abstract][Full Text] [Related]
2. Development of a transformer model for predicting the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation. Sato M; Moriyama M; Fukumoto T; Yamada T; Wake T; Nakagomi R; Nakatsuka T; Minami T; Uchino K; Enooku K; Nakagawa H; Shiina S; Koike K; Fujishiro M; Tateishi R Hepatol Int; 2024 Feb; 18(1):131-137. PubMed ID: 37689614 [TBL] [Abstract][Full Text] [Related]
3. Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals. Minami T; Sato M; Toyoda H; Yasuda S; Yamada T; Nakatsuka T; Enooku K; Nakagawa H; Fujinaga H; Izumiya M; Tanaka Y; Otsuka M; Ohki T; Arai M; Asaoka Y; Tanaka A; Yasuda K; Miura H; Ogata I; Kamoshida T; Inoue K; Nakagomi R; Akamatsu M; Mitsui H; Fujie H; Ogura K; Uchino K; Yoshida H; Hanajiri K; Wada T; Kurai K; Maekawa H; Kondo Y; Obi S; Teratani T; Masaki N; Nagashima K; Ishikawa T; Kato N; Yotsuyanagi H; Moriya K; Kumada T; Fujishiro M; Koike K; Tateishi R J Hepatol; 2023 Jun; ():. PubMed ID: 37716372 [TBL] [Abstract][Full Text] [Related]
4. A novel nomogram for prediction of intrahepatic recurrence-free survival in patients with HCC followed by radiofrequency ablation. Wang B; Wu H; Wang S; Zhang ZY; Wu W; Yan K; Yang W Br J Radiol; 2024 Mar; 97(1156):844-849. PubMed ID: 38346708 [TBL] [Abstract][Full Text] [Related]
5. Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning. Liu W; Wei R; Chen J; Li Y; Pang H; Zhang W; An C; Li C Eur Radiol; 2024 Aug; 34(8):5094-5107. PubMed ID: 38291256 [TBL] [Abstract][Full Text] [Related]
6. Machine learning-based personalized prediction of gastric cancer incidence using the endoscopic and histologic findings at the initial endoscopy. Arai J; Aoki T; Sato M; Niikura R; Suzuki N; Ishibashi R; Tsuji Y; Yamada A; Hirata Y; Ushiku T; Hayakawa Y; Fujishiro M Gastrointest Endosc; 2022 May; 95(5):864-872. PubMed ID: 34998795 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment. Liang X; Bu J; Jiang Y; Zhu S; Ye Q; Deng Y; Lu W; Liu Q Int J Hyperthermia; 2024; 41(1):2355279. PubMed ID: 38767372 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906 [TBL] [Abstract][Full Text] [Related]
9. Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study. Xin Y; Zhang X; Yang Y; Chen Y; Wang Y; Zhou X; Li X J Gastrointest Oncol; 2021 Dec; 12(6):2930-2942. PubMed ID: 35070419 [TBL] [Abstract][Full Text] [Related]
10. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Yang Y; Chen Y; Ye F; Cao X; Xin Y; Wang Y; Lei Y; Li X; Feng D; Zhou X; Fan Q Eur Radiol; 2021 May; 31(5):3053-3064. PubMed ID: 33175203 [TBL] [Abstract][Full Text] [Related]
11. Aspartate aminotransferase-to-platelet ratio index for predicting late recurrence of hepatocellular carcinoma after radiofrequency ablation. Zhang X; Xin Y; Yang Y; Chen Y; Cao XJ; Wang Y; Fan Q; Zhou X; Li X Int J Hyperthermia; 2022; 39(1):437-445. PubMed ID: 35249443 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Wang X; Liang H; Lu Z Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044 [No Abstract] [Full Text] [Related]
13. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. Mohkam K; Dumont PN; Manichon AF; Jouvet JC; Boussel L; Merle P; Ducerf C; Lesurtel M; Rode A; Mabrut JY J Hepatol; 2018 Jun; 68(6):1172-1180. PubMed ID: 29410287 [TBL] [Abstract][Full Text] [Related]
14. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. Peng Z; Wu X; Li J; Pang H; Zhang Y; Lin M; Wang Z; Xiao H; Li B; Chen M; Feng S; Kuang M; Chen S Int J Hyperthermia; 2022; 39(1):688-696. PubMed ID: 35469522 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance. Cao S; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J; Zou Y Cancer Imaging; 2022 Jan; 22(1):2. PubMed ID: 34983650 [TBL] [Abstract][Full Text] [Related]
16. Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C. Yamanaka Y; Shiraki K; Miyashita K; Inoue T; Kawakita T; Yamaguchi Y; Saitou Y; Yamamoto N; Nakano T; Nakatsuka A; Yamakado K; Takeda K World J Gastroenterol; 2005 Apr; 11(14):2174-8. PubMed ID: 15810088 [TBL] [Abstract][Full Text] [Related]
17. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Takada H; Tsuchiya K; Yasui Y; Nakakuki N; Tamaki N; Suzuki S; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Asahina Y; Enomoto N; Izumi N Cancer Med; 2016 Nov; 5(11):3111-3120. PubMed ID: 27748052 [TBL] [Abstract][Full Text] [Related]
18. Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study. Tan Y; Wang X; Ma K; Zhang L; Li J; Chen P; Zhang B Int J Hyperthermia; 2022; 39(1):190-199. PubMed ID: 35042449 [TBL] [Abstract][Full Text] [Related]
19. Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis. He Q; Xiong Y; Xia P; Yang X; Yu Y; Chen Z Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102283. PubMed ID: 38219821 [TBL] [Abstract][Full Text] [Related]
20. Outcomes of laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for hepatocellular carcinoma. Jeon HJ; Eun HS; Kwon IS; Lee BS; Lee ES; Rou WS; Sung JK; Moon HS; Kang SH; Lee HS; Kim SH; Chun K; Kim SH Surg Endosc; 2023 Jul; 37(7):5176-5189. PubMed ID: 36947227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]